ABPI response to PM's Brexit comments

The Prime Minister has said that the UK must prepare for 'no deal' but has indicated that negotiations between the EU and UK on the post-Brexit relationship will continue.

No deal is not in the interest of patients, the pharmaceutical industry, or the economies of the UK and the EU. Richard Torbett

In response, Richard Torbett, Chief Executive of the ABPI said:

“No deal is not in the interest of patients, the pharmaceutical industry, or the economies of the UK and the EU. As long as a window of opportunity remains, negotiators must keep talking and agree a comprehensive deal.

“They must ensure medicines supplies are uninterrupted and that a way forward for patients in Northern Ireland is urgently found.

"Our members are preparing for the end of the transition period at the same time as coronavirus cases rise across Europe. This should be enough to focus minds.”

TAGS
  • UK and EU future relationship

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.